Wegovy Pill Delivers 4.1% Weight Loss in Patients Switching From Injectables, Real-World OCTANE Data Show

Adults with overweight or obesity who switched from an injectable GLP-1-based weight-loss medicine to once-daily oral semaglutide (Wegovy pill) lost an average of 4.1% of their body weight, or 4.0 kg (8.8 lb), after 3 months, according to real-world data Novo Nordisk announced on Sept. 30, 2026.¹ The findings, from the OCTANE study, were presented in a short oral session at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy.¹

What did the OCTANE study evaluate?

OCTANE was a retrospective cohort analysis of de-identified data from the Ro telehealth platform. It is the first analysis in a previously announced collaboration between Ro and Novo Nordisk examining real-world outcomes among weight-loss medication users.¹ The study included adults with obesity, or with overweight (BMI 27 to 29.9 kg/m²) plus at least one obesity-related complication such as hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. People with diabetes or a history of bariatric surgery were excluded.¹

Participants switched from injectable semaglutide or tirzepatide to oral semaglutide between Jan. 5 and Feb. 7, 2026. They were not required to have used an injectable for any set period, or to have lost weight on it, to be included.¹ To be analyzed, patients had to stay on oral semaglutide through the 3-month follow-up without a gap of more than 30 days and have self-reported weights at baseline and at 3 months.¹

The final sample included 194 patients with a mean baseline weight of 100.5 kg (221.6 lb) and a mean BMI of 34.5 kg/m². On average, 36.8 days passed between the last injectable prescription and the start of oral semaglutide.¹

What were the results?

Mean weight loss at 3 months was 4.1% (p<0.001).¹ Two in five participants (40.7%) achieved weight loss of 5% or more. The share of participants with a BMI of 30 kg/m² or higher fell from 87.1% at baseline to 65.5%, a decrease of 21.6 percentage points (p<0.001).¹

Among participants with available data, 82.4% reported at least one treatment improvement on a predefined checklist, including better-fitting clothes (about 69%) and healthier eating (about 51%).¹

"In everyday clinical practice, we see patients who respond well to injectable GLP-1 based therapy but who, for personal or practical reasons, want to try an oral option," said Louis J. Aronne, MD, director of the Comprehensive Weight Control Center at Weill Cornell Medicine and a co-author of the study. "What the OCTANE data showed is that a switch to oral semaglutide may be a viable path for the right patient, with real weight loss and lifestyle improvements in the first three months."¹

What are the study's limitations?

Novo Nordisk noted that real-world studies evaluate associations and cannot determine causality, and that they complement randomized controlled trials, which are the gold standard for evaluating safety and efficacy.¹ Limitations the company cited for OCTANE include:

• variable timing and completeness of data collected during routine telehealth care
• potential bias in self-reported data
• possible selection bias from requiring treatment persistence
• results that may not be generalizable to the broader population¹

How does this fit with the pill's clinical data?

FDA approved the Wegovy pill (semaglutide 25 mg) on Dec. 22, 2025, as the first oral GLP-1 for weight loss in adults, for use with a reduced-calorie diet and increased physical activity.² The approval was supported by the 64-week phase 3 OASIS 4 trial. In that trial, patients who remained on treatment lost an average of 16.6% of body weight, versus 2.7% with placebo.²

Semaglutide injection 2.4 mg and semaglutide tablets 25 mg carry a Boxed Warning for possible thyroid tumors, including cancer. They should not be used in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.¹ The most common side effects include nausea, diarrhea, vomiting, and constipation.¹

What happens next?

The Wegovy pill has launched in the US, the United Arab Emirates, the UK, and Germany, and Novo Nordisk plans to launch it in select markets in the coming quarters.¹

"These are exciting early insights on how the pill can individualize obesity care, and we look forward to seeing longer-term outcomes," Aronne said.¹

References

1. Novo Nordisk. People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on average after three months, according to real-world data presented at EASD2026. Press release. Published September 30, 2026. Accessed September 30, 2026.
2. Novo Nordisk. FDA approves Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults. Press release. Published December 22, 2025. Accessed September 30, 2026.
3. Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med. 2025;393(11):1077-1087. Published online September 17, 2025. doi:10.1056/NEJMoa2500969